Search

Your search keyword '"Knisbacher, Binyamin A."' showing total 12 results
Start Over Author "Knisbacher, Binyamin A." Publisher american society of hematology
12 results on '"Knisbacher, Binyamin A."'

1. IGLV3-21R110 mutation has prognostic value in patients with treatment-naive chronic lymphocytic leukemia

Author

Syrykh, Charlotte, primary, Pons-Brun, Berta, additional, Russiñol, Núria, additional, Playa-Albinyana, Heribert, additional, Baumann, Tycho, additional, Duran-Ferrer, Martí, additional, Kulis, Marta, additional, Carbó-Meix, Anna, additional, Mozas, Pablo, additional, Alcoceba, Miguel, additional, González, Marcos, additional, Navarro-Bailón, Almudena, additional, Colado, Enrique, additional, Payer, Ángel R., additional, Aymerich, Marta, additional, Terol, María J., additional, Lu, Junyan, additional, Knisbacher, Binyamin A., additional, Hahn, Cynthia K., additional, Ruiz-Gaspà, Sílvia, additional, Enjuanes, Anna, additional, Wu, Catherine J., additional, Getz, Gad, additional, Zenz, Thorsten, additional, López-Guillermo, Armando, additional, Martín-Subero, José I., additional, Colomer, Dolors, additional, Delgado, Julio, additional, Campo, Elías, additional, and Nadeu, Ferran, additional

Published
2023
Full Text
View/download PDF

2. IGLV3-21R110 mutation has prognostic value in patients with treatment-naive chronic lymphocytic leukemia

Author

Fundación la Caixa, Ministerio de Ciencia e Innovación (España), Agencia Estatal de Investigación (España), Instituto de Salud Carlos III, European Commission, Generalitat de Catalunya, National Institutes of Health (US), National Cancer Institute (US), Centro de Investigación Biomédica en Red Cáncer (España), Ministerio de Universidades (España), Fundación Científica Asociación Española Contra el Cáncer, National Heart, Lung, and Blood Institute (US), American Association for Cancer Research, Lady Tata Memorial Trust, Institución Catalana de Investigación y Estudios Avanzados, Centro Esther Koplowitz, Syrykh, Charlotte, Pons-Brun, Berta, Russiñol, Núria, Playa-Albinyana, Heribert, Baumann, Tycho, Duran-Ferrer, Martí, Kulis, Marta, Carbó-Meix, Anna, Mozas, Pablo, Alcoceba, Miguel, González, Marcos, Navarro-Bailón, Almudena, Colado, Enrique, Payer, Ángel R., Aymerich, Marta, Terol, María J., Lu, Junyan, Knisbacher, Binyamin A., Hahn, Cynthia K., Ruiz-Gaspà, Sílvia, Enjuanes, Anna, Wu, Catherine J., Getz, Gad, Zenz, Thorsten, López-Guillermo, Armando, Martín-Subero, José I., Colomer, Dolors, Delgado, Julio, Campo, Elías, Nadeu, Ferran, Fundación la Caixa, Ministerio de Ciencia e Innovación (España), Agencia Estatal de Investigación (España), Instituto de Salud Carlos III, European Commission, Generalitat de Catalunya, National Institutes of Health (US), National Cancer Institute (US), Centro de Investigación Biomédica en Red Cáncer (España), Ministerio de Universidades (España), Fundación Científica Asociación Española Contra el Cáncer, National Heart, Lung, and Blood Institute (US), American Association for Cancer Research, Lady Tata Memorial Trust, Institución Catalana de Investigación y Estudios Avanzados, Centro Esther Koplowitz, Syrykh, Charlotte, Pons-Brun, Berta, Russiñol, Núria, Playa-Albinyana, Heribert, Baumann, Tycho, Duran-Ferrer, Martí, Kulis, Marta, Carbó-Meix, Anna, Mozas, Pablo, Alcoceba, Miguel, González, Marcos, Navarro-Bailón, Almudena, Colado, Enrique, Payer, Ángel R., Aymerich, Marta, Terol, María J., Lu, Junyan, Knisbacher, Binyamin A., Hahn, Cynthia K., Ruiz-Gaspà, Sílvia, Enjuanes, Anna, Wu, Catherine J., Getz, Gad, Zenz, Thorsten, López-Guillermo, Armando, Martín-Subero, José I., Colomer, Dolors, Delgado, Julio, Campo, Elías, and Nadeu, Ferran

Abstract

Chronic lymphocytic leukemia (CLL) has high biological and clinical heterogeneity.1,2 A few prognostic factors are used in clinical practice, including immunoglobulin heavy-chain variable (IGHV) gene somatic hypermutation (SHM) status, chromosome aberrations, and gene mutations, which remain insufficient for personalized patient management.3,4 Recent studies have shown that expression of the immunoglobulin lambda light chain IGLV3-21 gene carrying an SHM-derived G>C mutation changing the glycine at position 110 to an arginine (IGLV3-21R110) defines a subset of CLL with an intermediate epigenetic profile and an aggressive clinical course.5,6 When occurring on the IGLV3-21∗01 or ∗04 alleles, the R110 mutation allows homotypic B-cell receptor (BCR) interactions, triggering cell-autonomous BCR signaling5,7 and/or facilitating T-cell–independent engagement with superantigen.8 IGLV3-21R110 has been detected in up to 6.5% of patients with CLL at diagnosis and in up to 25% of patients enrolled in clinical trials.5,6,9 We6 and others5 have shown that all CLL cases belonging to aggressive stereotyped subset #2 carried the IGLV3-21R110. Nonetheless, approximately half of IGLV3-21R110 CLL are not classified as stereotyped subset #2 but seem to have a similar clinical outcome,5,6 suggesting that the conventional stereotyped subset #2 classification might not completely recognize this clinically aggressive subgroup of CLL. In addition, IGLV3-21R110 seems to have a prognostic value independent of the IGHV gene SHM status and methylation–based epigenetic subtypes.5,6 However, further studies in independent cohorts are needed to support its application in clinical practice.1,2,10-12 The aim of this study was to assess the prognostic value of IGLV3-21R110 in large and independent population-based cohorts of patients with CLL.

Published
2023

3. IGLV3-21$^{R110}$ mutation has prognostic value in patients with treatment-naive chronic lymphocytic leukemia

Author

Nadeu, Ferran; https://orcid.org/0000-0003-2910-9440, Syrykh, Charlotte, Pons-Brun, Berta, Russiñol, Núria, Playa-Albinyana, Heribert; https://orcid.org/0000-0002-3447-3848, Baumann, Tycho Stephan, Duran-Ferrer, Martí; https://orcid.org/0000-0003-1666-5819, Kulis, Marta; https://orcid.org/0000-0001-8104-9620, Carbó-Meix, Anna, Mozas, Pablo; https://orcid.org/0000-0001-9528-4971, Alcoceba, Miguel, González, Marcos; https://orcid.org/0000-0001-6637-1072, Navarro-Bailón, Almudena; https://orcid.org/0000-0002-7972-5666, Colado, Enrique, Payer, Ángel, Aymerich, Marta, Terol, María José, Lu, Junyan; https://orcid.org/0000-0002-9211-0746, Knisbacher, Binyamin Asher; https://orcid.org/0000-0002-4962-9956, Hahn, Cynthia K; https://orcid.org/0000-0001-8284-7261, Ruiz-Gaspà, Sílvia, Enjuanes, Anna, Wu, Catherine J; https://orcid.org/0000-0002-3348-5054, Getz, Gad, Zenz, Thorsten; https://orcid.org/0000-0001-7890-9845, López-Guillermo, Armando, Martin-Subero, Jose I; https://orcid.org/0000-0001-8809-5195, Colomer, Dolors, Delgado, Julio; https://orcid.org/0000-0002-5157-4376, Campo, Elías; https://orcid.org/0000-0001-9850-9793, Nadeu, Ferran; https://orcid.org/0000-0003-2910-9440, Syrykh, Charlotte, Pons-Brun, Berta, Russiñol, Núria, Playa-Albinyana, Heribert; https://orcid.org/0000-0002-3447-3848, Baumann, Tycho Stephan, Duran-Ferrer, Martí; https://orcid.org/0000-0003-1666-5819, Kulis, Marta; https://orcid.org/0000-0001-8104-9620, Carbó-Meix, Anna, Mozas, Pablo; https://orcid.org/0000-0001-9528-4971, Alcoceba, Miguel, González, Marcos; https://orcid.org/0000-0001-6637-1072, Navarro-Bailón, Almudena; https://orcid.org/0000-0002-7972-5666, Colado, Enrique, Payer, Ángel, Aymerich, Marta, Terol, María José, Lu, Junyan; https://orcid.org/0000-0002-9211-0746, Knisbacher, Binyamin Asher; https://orcid.org/0000-0002-4962-9956, Hahn, Cynthia K; https://orcid.org/0000-0001-8284-7261, Ruiz-Gaspà, Sílvia, Enjuanes, Anna, Wu, Catherine J; https://orcid.org/0000-0002-3348-5054, Getz, Gad, Zenz, Thorsten; https://orcid.org/0000-0001-7890-9845, López-Guillermo, Armando, Martin-Subero, Jose I; https://orcid.org/0000-0001-8809-5195, Colomer, Dolors, Delgado, Julio; https://orcid.org/0000-0002-5157-4376, and Campo, Elías; https://orcid.org/0000-0001-9850-9793

Published
2023

4. Proteogenomic Analysis of SF3B1 mut CLL Reveals Altered Protein Signaling Cascades and Metabolomic Pathways

Author

Klaeger, Susan, primary, Tausch, Eugen, additional, Knisbacher, Binyamin A., additional, Apffel, Annie, additional, Clauser, Karl R, additional, Williams, Corinne, additional, Clish, Clary, additional, Rassenti, Laura Z., additional, Kipps, Thomas J., additional, Fischer, Kirsten, additional, Hallek, Michael, additional, Gillette, Michael A, additional, Neuberg, Donna S., additional, Getz, Gad, additional, Mani, DR, additional, Stilgenbauer, Stephan, additional, Wu, Catherine J., additional, and Carr, Steven A, additional

Published
2022
Full Text
View/download PDF

5. Association of Clonal Hematopoiesis of Indeterminate Potential with Time to First Treatment, Incidence of Richter's Syndrome, and Overall Survival in Patients with Chronic Lymphocytic Leukemia

Author

Vijenthira, Abi, primary, Sekar, Aswin, additional, Gibson, Christopher J., additional, Martindale, Stephen P., additional, Fardoun, Rayan, additional, Tyekucheva, Svitlana, additional, Ren, Yue, additional, Fernandes, Stacey M., additional, Knisbacher, Binyamin A., additional, Hahn, Cynthia K., additional, Getz, Gad, additional, Wu, Catherine J., additional, Davids, Matthew S., additional, and Brown, Jennifer R., additional

Published
2022
Full Text
View/download PDF

7. Prevalence of Clonal Hematopoiesis of Indeterminate Potential in Patients with Monoclonal B-Cell Lymphocytosis Compared to Untreated Chronic Lymphocytic Leukemia

Author

Patel, Anisha V., primary, Vijenthira, Abirami, additional, Sekar, Aswin, additional, Gibson, Christopher J., additional, Martindale, Stephen P., additional, Fardoun, Rayan, additional, Tyekucheva, Svitlana, additional, Fernandes, Stacey M., additional, Knisbacher, Binyamin A., additional, Hahn, Cynthia K., additional, Getz, Gad, additional, Wu, Catherine J., additional, Davids, Matthew S., additional, and Brown, Jennifer R., additional

Published
2022
Full Text
View/download PDF

8. Evolutionary History of Transformation from Chronic Lymphocytic Leukemia to Richter Syndrome

Author

Parry, Erin Michelle, primary, Guieze, Romain, additional, Leshchiner, Ignaty, additional, Johnson, Connor, additional, Tausch, Eugen, additional, Parikh, Sameer A., additional, Lemvigh, Camilla K, additional, Broséus, Julien, additional, Hergalant, Sébastien, additional, Messer, Connor, additional, Utro, Filippo, additional, Levovitz, Chaya, additional, Rhrissorrakrai, Kahn, additional, Li, Liang, additional, Li, Shuqiang, additional, Fell, Geoffrey G, additional, Redd, Robert A., additional, Lin, Ziao, additional, Knisbacher, Binyamin A., additional, Schneider, Christof, additional, Fernandes, Stacey M., additional, Hess, Julian M., additional, Rassenti, Laura Z., additional, Kipps, Thomas J., additional, Jain, Nitin, additional, Wierda, William G., additional, Cymbalista, Florence, additional, Feugier, Pierre, additional, Kay, Neil E., additional, Livak, Kenneth J, additional, Danysh, Brian P, additional, Stewart, Chip, additional, Neuberg, Donna S., additional, Davids, Matthew S., additional, Brown, Jennifer R., additional, Parida, Laxmi, additional, Stilgenbauer, Stephan, additional, Getz, Gad, additional, and Wu, Catherine J., additional

Published
2022
Full Text
View/download PDF

9. ZNF683 (Hobit) Marks a CD8+ T Cell Population Associated with Anti-Tumor Immunity Following Anti-PD-1 Therapy for Richter Syndrome

Author

Lemvigh, Camilla K, primary, Parry, Erin Michelle, additional, Deng, Stephanie L, additional, Dangle, Nathan J, additional, Ruthen, Neil, additional, Knisbacher, Binyamin A., additional, Broséus, Julien, additional, Hergalant, Sébastien, additional, Guieze, Romain, additional, Li, Shuqiang, additional, Yin, Shanye, additional, Huang, Teddy, additional, Livak, Kenneth J, additional, Getz, Gad, additional, Neuberg, Donna S., additional, Feugier, Pierre, additional, Kharchenko, Peter, additional, Wierda, William G., additional, Olsen, Lars Rønn, additional, Jain, Nitin, additional, and Wu, Catherine J., additional

Published
2022
Full Text
View/download PDF

10. The CLL-1100 Project: Towards Complete Genomic Characterization and Improved Prognostics for CLL

Author

Knisbacher, Binyamin A., primary, Lin, Ziao, additional, Hahn, Cynthia K., additional, Nadeu, Ferran, additional, Duran-Ferrer, Martí, additional, Stevenson, Kristen E., additional, Tausch, Eugen, additional, Barbera-Mourelle, Alex, additional, Dunford, Andrew, additional, Anand, Shankara, additional, Delgado, Julio, additional, Hess, Julian M., additional, Taylor-Weiner, Amaro, additional, Kretzmer, Helene, additional, Bousquets Muñoz, Pablo, additional, Shaughnessy, Conner J., additional, Fernandes, Stacey M., additional, Sivina, Mariela, additional, Rassenti, Laura Z., additional, Meissner, Alexander, additional, Wiestner, Adrian, additional, Burger, Jan A., additional, Kipps, Thomas J., additional, Brown, Jennifer R, additional, Hallek, Michael, additional, Aguet, François, additional, Neuberg, Donna S., additional, Puente, Xose S, additional, Stewart, Chip, additional, Martín-Subero, José I., additional, Stilgenbauer, Stephan, additional, Wu, Catherine J., additional, Campo, Elías, additional, and Getz, Gad, additional

Published
2020
Full Text
View/download PDF

11. RPS15 and TP53 Co-Mutation Drives B Cell Malignancy through Altered Translation and MYC Activation in a Murine Model

Author

Gutierrez, Catherine, primary, Ouspenskaia, Tamara, additional, Fu, Doris, additional, Waddicor, Peyton, additional, Biran, Anat, additional, Liani, Aviv, additional, Lazarian, Gregory, additional, Ten Hacken, Elisa, additional, Witten, Elizabeth, additional, Regis, Fara Faye, additional, Joyal, Heather, additional, Billington, Leah, additional, Lucas, Fabienne, additional, Zheng, Mei, additional, Tye, Blake, additional, Hernandez-Sanchez, Maria, additional, Quijada Álamo, Miguel, additional, Li, Shuqiang, additional, Knisbacher, Binyamin A., additional, Lin, Ziao, additional, Al'Khafaji, Aziz, additional, Wang, Lili, additional, Livak, Kenneth J., additional, Neuberg, Donna S., additional, Cymbalista, Florence, additional, Getz, Gad, additional, Churchman, Stirling, additional, Carrasco, Ruben D., additional, Shao, Sichen, additional, Regev, Aviv, additional, and Wu, Catherine J., additional

Published
2020
Full Text
View/download PDF

12. Myeloid clonal hematopoiesis of indeterminate potential in patients with chronic lymphocytic leukemia.

Author

Vijenthira A, Volpe VO, Sekar A, Santos Azevedo R, Mikhaleva M, Gibson CJ, Martindale SP, Fardoun R, Tyekucheva S, Ren Y, Fernandes SM, Knisbacher BA, Hahn CK, Getz G, Wu CJ, Davids MS, and Brown JR

Subjects
Humans, Female, Aged, Male, Middle Aged, High-Throughput Nucleotide Sequencing, Retrospective Studies, Aged, 80 and over, Adult, Prognosis, Leukemia, Lymphocytic, Chronic, B-Cell genetics, Leukemia, Lymphocytic, Chronic, B-Cell mortality, Leukemia, Lymphocytic, Chronic, B-Cell diagnosis, Clonal Hematopoiesis, Mutation
Abstract

Abstract: Clonal hematopoiesis of indeterminate potential (CHIP) in patients with chronic lymphocytic leukemia (CLL) has not been extensively characterized. The objective of this study was to describe the prevalence of myeloid CHIP (M-CHIP) in patients with CLL, and to determine its association with time to first treatment (TTFT) and overall survival (OS). We retrospectively analyzed data from patients participating in a prospective CLL database at the Dana-Farber Cancer Institute who had standard-of-care targeted 95-gene next-generation sequencing (NGS) performed. A schema was devised to classify mutations as M-CHIP related. M-CHIP was analyzed as a binary (present/absent) and categorical (≥2 vs 1 vs 0 mutations) predictor. We included 966 patients (median age at time of NGS, 65 years; 38% female). Overall, 747 (77%) patients had NGS performed before CLL treatment, whereas 219 (23%) had it performed after receiving treatment. Median follow-up time from NGS was 1.9 years. The prevalence of M-CHIP in untreated (12%) and treated (24%) patients with CLL was similar to that described in previous literature. M-CHIP prevalence appeared to increase with age in untreated patients, but appeared consistent across age in treated patients, suggesting that treatment (85% had prior chemotherapy) may have an impact on M-CHIP emergence even in younger patients. The presence of ≥2 M-CHIP mutations was associated with OS, even accounting for prior treatment and age, but was driven by a small subset of patients (n = 28). M-CHIP was not associated with TTFT. These findings support continued work into characterizing the effects of M-CHIP in patients with CLL., (© 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results